Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as ...

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for ...

We’ve all heard someone turn to a friend, colleague or stranger who is struggling with their weight and mutter the words: “it ...

The five-year SURMOUNT-REAL UK trial, part of a collaboration signed last year between Lilly and the UK government, will ...

As of February 2025, just 800 Brits were still receiving ESA for obesity, representing a 43% decrease from 2020. The Department for Work and Pensions (DWP) is in the process of moving all remaining ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive Weight Loss Programme to customers.

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor ...

The FDA approval was secured following a pivotal clinical trial carried out across the US and UK, with the UK site overseen ...

NEW figures have revealed more than 300,000 Scots are now on weight-loss drugs. And while users report remarkable results, ...

Eli Lilly (NYSE:LLY) shares rose about 2% on early Thursday after the company said a pivotal study for its experimental ...